



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

12th February, 2026

Corporate Relationship Department
BSE Limited
Mumbai 400001

The Manager - Listing
National Stock Exchange of India Ltd
Mumbai 400051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors at their meeting held today approved the following:

1. Superannuation of Mr. S.V.V.N. Appa Rao, Chief Financial Officer w.e.f. closure of the business hours of 12th February, 2026.
2. Appointment of Mr. Amit Parekh, Executive Vice President – Finance and Accounts as Chief Financial Officer of the Company w.e.f. 13th February, 2026.
3. Appointment of Mr. Kalakuntla Srinivas Rao as Executive Vice President – Pharma Division of the Company w.e.f. 12th February, 2026.

The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December 2024 is enclosed as Annexure.

This is for your information and records.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl.: As above



Annexure

Sl. No.	Particulars			
1	Name	Mr. S.V.V.N. Appa Rao	Mr. Amit Parekh	Mr. Kalakuntla Srinivas Rao
2	Reason for Change in Senior Management/ KMP	Superannuation	Appointed as Chief Financial Officer of the Company	Appointed as Executive Vice President – Pharma Division
3	Date of Appointment / Cessation & Term of Appointment	Closure of the business hours of 12 th February, 2026	13 th February, 2026 & Terms of appointment are as per the Company's Policy	12 th February, 2026 & Terms of appointment are as per the Company's Policy
4	Brief profile	Not Applicable	Mr. Amit Parekh has more than 23 years of experience, with a proven track record of managing financial and business affairs for top Indian companies in diverse industries, including healthcare, pharma, mining and engineering, telecommunications, and chemicals. Few of his core competencies are CXO Level engagements, Investment & M&A (including in & out licencing deals in Pharma space), Cost leadership Projects, Financial Analysis and Reporting, Financial Management & Accounting (IFRS, IND AS, US GAAP) and Risk Assessment & Compliance, etc., he was previously associated with Dr. Reddy's Laboratories Limited as Head of Finance - API and Pharmaceutical Services (PSAI) and Head of Digital Transformation in Finance. He is currently working as Executive Vice President – Finance & Accounts of the Company.	Mr. Kalakuntla Srinivas Rao has more than 25 years of experience. He is admired for sound & practical management style with emphasis on revenue driven models and strategies. He is growth-oriented including Japan networked operations with proven results and repeated success in multiple units and achieving critical strategic goals. He has showed adherence to compliance with respect to USFDA, PMDA, MHRA, cGMP, validation, selection and qualification of product and equipment including new facility design & setup. He was previously associated with MSN Laboratories Private Limited as EVP Formulation Operations and Lupin Limited as Senior Vice President (Cluster Head), etc.
5	Disclosure of relationship between Directors	Not Applicable	Not Applicable	Not Applicable